Cannabis Science Inc (fka CBIS)

[sicofbs]

Oh Dabney ..how about an update due...lol....yourmsuchna creep it's frightening you've gotten away with this for so long ....call me if I'm wrong Dabney...lol


COLORADO SPRINGS, Colo., Jan. 5, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce the International release of 8 initial products that will be synergistically produced, distributed and marketed across the Netherlands, Spain and California where Cannabis Science is active and has cannabis production facilities.

The products are currently ready for pre-clinical studies, self-medicating patient ailment usage, marketing release, sales and distribution. The roll-out will involve Cannabis Science teams in both Europe and California to work in tandem to share information, send formulations to be produced in each respective production facility and share patient indicators based on usage metrics to scale demand, while collecting insightful data in each geographical market appropriately. Different logistical capabilities will be developed through internal management to adequately produce, distribute and market products along with the proper procurement of opt-in, informed consent patient data from outcomes to establish Cannabis Science with a vertically integrated product pipeline to accommodate international markets.

Cannabis Science will be announcing shortly where products are available for purchase in each jurisdiction; initial cannabis formulations will be focused on:

Topical formulations for cancers
Ingestible formulations for cancers, HIV/AIDS and other indications
Varied formulations for neurological disorders and other indications depending on delivery methodology required
Ingestible and topical formulations for chemotherapy side effects, chronic pain, muscle problems, sleeping disorders, nausea, ADHD, rheumatism, arthritis, infections, diabetes, manic depression, fibromyalgia and other issues
Topical formulations for rheumatism, fibromyalgia, arthritis, eczema, sporting injuries, radiotherapy wounds, muscle and neck pain, radiotherapy wounds, rheumatism, open wounds and sensitive and irritated skin, various skin complaints, and wounds
The Cannabis Science Patient Access Center (PAC) http://pac.cannabisscience.com, released in beta version, is now available for patients to track usage and receive updates.

"With the proper distribution channels in place to reach large ranges of patients in different prognosis situations, we intend on releasing our cannabis formulations with specific support channels and applications to provide consumers adequate insight into product specifications, usage recommendations and the opt-in ability to input a variety of sentiments across medical indicators for the appropriate monitoring of effects. Our Scientific Advisory Board and management team is working towards the development of a vertically integrated model to standardize aforementioned practices for multiple other jurisdictions and regulatory environments to accommodate the growth of the sector," stated Mr. Raymond C. Dabney, Director, President & CEO, Co-Founder, Cannabis Science, Inc.